{"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"groups":[{"description":"Administered orally QD for initial 12 weeks (Part A) followed by randomization to either 4 mg QD or 2 mg BID for an additional 12 weeks (Part B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment, participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.\n\nMTX was administered orally as background therapy.","id":"BG000","title":"1 mg LY3009104"},{"description":"Administered orally QD for 24 weeks (Parts A and B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment, participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.\n\nMTX was administered orally as background therapy.","id":"BG001","title":"2 mg LY3009104"},{"description":"Administered orally QD for 24 weeks (Parts A and B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment, participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.\n\nMTX was administered orally as background therapy.","id":"BG002","title":"4 mg LY3009104"},{"description":"Administered orally QD for 24 weeks (Parts A and B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment, participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.\n\nMTX was administered orally as background therapy.","id":"BG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for initial 12 weeks (Part A) followed by randomization to either 4 mg QD or 2 mg BID for an additional 12 weeks (Part B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.\n\nMTX was administered orally as background therapy.","id":"BG004","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.07","value":"53.1"},{"groupId":"BG001","spread":"13.12","value":"50.7"},{"groupId":"BG002","spread":"10.42","value":"52.5"},{"groupId":"BG003","spread":"10.91","value":"52.7"},{"groupId":"BG004","spread":"12.15","value":"49.2"},{"groupId":"BG005","spread":"11.71","value":"51.2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"41"},{"groupId":"BG004","value":"85"},{"groupId":"BG005","value":"249"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"52"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"56"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"36"},{"groupId":"BG004","value":"78"},{"groupId":"BG005","value":"227"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"18"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"19"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"47"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"11"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"70"},{"groupId":"BG005","value":"224"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"95"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"13"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"23"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"Czech Republic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"47"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"Mexico"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"33"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"29"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"Ukraine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"Croatia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"11"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"Romania"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"43"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}],"title":"India"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.885","value":"5.45"},{"groupId":"BG001","spread":"4.377","value":"5.53"},{"groupId":"BG002","spread":"4.466","value":"5.28"},{"groupId":"BG003","spread":"5.048","value":"6.63"},{"groupId":"BG004","spread":"4.283","value":"5.40"},{"groupId":"BG005","spread":"4.401","value":"5.62"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Duration of Rheumatoid Arthritis","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.90","value":"21.4"},{"groupId":"BG001","spread":"12.60","value":"23.0"},{"groupId":"BG002","spread":"12.71","value":"19.9"},{"groupId":"BG003","spread":"13.76","value":"24.4"},{"groupId":"BG004","spread":"12.06","value":"22.2"},{"groupId":"BG005","spread":"12.38","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}]}],"description":"TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Tender Joint Counts (TJC)","unitOfMeasure":"number of joints"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.55","value":"15.2"},{"groupId":"BG001","spread":"9.32","value":"17.0"},{"groupId":"BG002","spread":"7.54","value":"14.8"},{"groupId":"BG003","spread":"7.92","value":"16.1"},{"groupId":"BG004","spread":"8.64","value":"15.8"},{"groupId":"BG005","spread":"8.13","value":"15.8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}]}],"description":"SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Swollen Joint Counts (SJC)","unitOfMeasure":"number of joints"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.410","value":"11.22"},{"groupId":"BG001","spread":"22.111","value":"12.02"},{"groupId":"BG002","spread":"16.941","value":"11.39"},{"groupId":"BG003","spread":"15.602","value":"14.32"},{"groupId":"BG004","spread":"23.527","value":"14.03"},{"groupId":"BG005","spread":"19.402","value":"12.81"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"97"},{"groupId":"BG005","value":"300"}],"units":"Participants"}]}],"description":"HsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"All randomized participants who received at least one dose of study drug and had evaluable hsCRP data at baseline.","title":"High Sensitivity C-Reactive Protein (hsCRP)","unitOfMeasure":"milligrams/liter (mg/L)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"17.57","value":"38.2"},{"groupId":"BG001","spread":"14.62","value":"36.5"},{"groupId":"BG002","spread":"17.16","value":"35.4"},{"groupId":"BG003","spread":"18.17","value":"43.3"},{"groupId":"BG004","spread":"20.94","value":"39.9"},{"groupId":"BG005","spread":"18.39","value":"38.8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"301"}],"units":"Participants"}]}],"description":"ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Erythrocyte Sedimentation Rate (ESR)","unitOfMeasure":"millimeters/hour (mm/hr)"}],"populationDescription":"All randomized participants who received at least 1 dose of study drug."}